Inclusion Criteria:

          -  ECOG performance status of 0 or 1

          -  Life expectancy of at least 12 weeks

          -  Histologically or cytologically documented invasive CRC: incurable, unresectable,
             locally advanced or metastatic CRC previously treated with multimodality therapy or
             mCRC

          -  Locally advanced or metastatic CRC that has relapsed or is refractory to established
             therapies

          -  Prior disease progression (or intolerance) following oxaliplatin, irinotecan,
             fluoropyrimidines, and anti-EGFR monoclonal antibodies

          -  An archival tissue specimen or fresh baseline biopsy (when archival is not available)
             is required for enrollment into the study

          -  Measurable disease, according to the Response Evaluation Criteria in Solid Tumors
             (RECIST) v1.1. Non-measurable evaluable disease is acceptable for dose-escalation.

          -  Adequate hematologic and end organ function

          -  Acute, clinically significant treatment-related toxicity from prior therapy resolved
             to Grade ≤ 1 prior to study entry

        Expansion Cohort-Specific Inclusion Criteria

          -  MSS or MSI-L disease as determined by polymerase chain reaction (PCR) and/or IHC

          -  Measurable disease by RECIST v1.1 with at least one measurable target lesion in the
             expansion cohort

          -  Progression must have occurred during or after most recent treatment for locally
             advanced or metastatic colorectal cancer

        Exclusion Criteria:

          -  Pregnant or breastfeeding, or intending to become pregnant during the study or within
             4 months after the final dose of BLYG8824A

          -  Significant cardiopulmonary dysfunction

          -  Known clinically significant liver disease

          -  Positive serologic or PCR test results for acute or chronic HBV infection

          -  Acute or chronic HCV infection

          -  HIV seropositivity

          -  Poorly controlled Type 2 diabetes mellitus

          -  Current treatment with medications that are well known to prolong the QT interval

          -  Primary CNS malignancy, untreated CNS metastases, or active CNS metastases

          -  Leptomeningeal disease

          -  Spinal cord compression that has not been definitively treated with surgery and/or
             radiation

          -  History of autoimmune disease

          -  Prior allogeneic stem cell or solid organ transplantation